clinical trial · NCT06264388
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
Ashish Shah·phase2·recruiting·n = 33
High Grade GliomaAnaplastic AstrocytomaDB107-RRVDB107-FC
brief summary
The purpose of this study is to determine if the investigational products, DB107-RRV and DB107-FC, as a combination treatment will shrink high-grade glioma (HGG) in patients with recurrent/progressive, resectable or unresectable disease and increase the time that disease is controlled.
started
May 1, 2024
primary completion
May 1, 2034
completion
May 1, 2034
last updated
May 29, 2025
official title
A Biomarker-Guided Phase 2 Study of DB107-RRV (Retroviral Replicating Vector) Combined With DB107-Flucytosine Extended-Release Tablets in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol